Sign in
Not yet taking people in FinlandPhase 1/2

Scan tracer [68Ga]Ga-DOTA-SIGLEC-9 in rheumatoid arthritis, vasculitis and lung sarcoidosis

Tests an imaging tracer's safety and body spread in inflammatory disease patients and healthy volunteers.

Key facts

Who runs it
Turku University Hospital
Where
Turku, FinlandSee the site
Registry title
POSITRON EMISSION TOMOGRAPHY/COMPUTED TOMOGRAPHY STUDY FOR SAFETY, TOLERABILITY, BIODISTRIBUTION AND PERFORMANCE OF [68Ga]Ga-DOTA-SIGLEC-9 FOLLOWING A SINGLE INTRAVENOUS ADMINISTRATION IN PATIENTS WITH ACTIVE RHEUMATOID ARTHRITIS, VASCULITIS OR PULMONARY SARCOIDOSIS AS WELL AS RADIATION DOSIMETRY, PLASMA PHARMACOKINETICS, BIODISTRIBUTION OF THE TRACER IN HEALTHY VOLUNTEERS
Status
Not yet recruiting
Phase
Phase 1/2
People taking part
26 people, planned
Started
1 Jan 2019
Expected to end
31 Dec 2029
Type of study
Interventional
Record updated
29 January 2025

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults with active rheumatoid arthritis, vasculitis or pulmonary sarcoidosis, and also healthy volunteers. Each person gets one dose of a tracer called [68Ga]Ga-DOTA-SIGLEC-9 given into a vein, followed by a PET/CT scan.

Age
18 Years and older
Sex
All sexes
Disease stage
Patients must have active rheumatoid arthritis, vasculitis or pulmonary sarcoidosis. Healthy volunteers can also join.

Where in Finland

  • Turku University HospitalTurku, FinlandNot yet recruiting

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record

Print a page for my doctor

Data and sources

Registry record
Listed on the EU's official list of trials (CTIS).How to verify a trial in the registry
Plain-language title
Scan tracer [68Ga]Ga-DOTA-SIGLEC-9 in rheumatoid arthritis, vasculitis and lung sarcoidosisGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 14 November 2026.
Record updated
29 January 2025